During the last several years,exciting discoveries have been made in prostate cancer (PCa) as a result of significant advances in genomic technology and information.For example,using genome-wide association studies,more than 100 inherited genetic variants associated with PCa risk have been identified.Similarly,with the use of next-generation sequencing,various types of recurrent somatic DNA alterations in prostate tumors have been revealed.Some of these discoveries have potential clinical application to supplement existing tools for better decision-making regarding the need for screening,biopsy,and treatment of PCa.